How hospitals can manage anticoagulant-related acute major bleeding
Thursday, September 12th, 2024 | 11:00 AM - 12:00 PM CT
While anticoagulants are vital in preventing thrombotic events, their use carries inherent risks, including the potential for uncontrolled bleeding. Over 500 patients a day are hospitalized for acute major bleeding in the U.S., about 90 of whom die from the complication.
This webinar, featuring a pharmacy professor from University of Nebraska Medical Center in Omaha, will offer best practices for hospitals to manage uncontrolled bleeding related to factor Xa inhibitors, including the value of reversal agents.
Learning points:
This webinar, featuring a pharmacy professor from University of Nebraska Medical Center in Omaha, will offer best practices for hospitals to manage uncontrolled bleeding related to factor Xa inhibitors, including the value of reversal agents.
Learning points:
- Review the top-line results of a prospective, randomized clinical trial in patients with ICH taking apixaban or rivaroxaban.
- Discuss clinical trials and real-world evidence studies of this reversal agent for apixaban and rivaroxaban in patients with acute major bleeding.